Cargando…
Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women.
Tamoxifen has been implicated as a risk factor for venous thrombosis in advanced breast cancer although the evidence for increased arterial or venous thrombosis with tamoxifen in early breast cancer is less clear. The effect of tamoxifen on haemostasis, and thereby possible thromboembolic risk, was...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1992
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977438/ https://www.ncbi.nlm.nih.gov/pubmed/1419616 |
_version_ | 1782135261814063104 |
---|---|
author | Jones, A. L. Powles, T. J. Treleaven, J. G. Burman, J. F. Nicolson, M. C. Chung, H. I. Ashley, S. E. |
author_facet | Jones, A. L. Powles, T. J. Treleaven, J. G. Burman, J. F. Nicolson, M. C. Chung, H. I. Ashley, S. E. |
author_sort | Jones, A. L. |
collection | PubMed |
description | Tamoxifen has been implicated as a risk factor for venous thrombosis in advanced breast cancer although the evidence for increased arterial or venous thrombosis with tamoxifen in early breast cancer is less clear. The effect of tamoxifen on haemostasis, and thereby possible thromboembolic risk, was investigated in normal women enrolled in a placebo controlled trial of tamoxifen as a chemopreventative agent for breast cancer. There was an initial reduction in fibrinogen levels in all women on tamoxifen over the first year of follow-up and a marginal reduction in antithrombin III and Protein S in postmenopausal women at 6 months. There were no changes in cross linked fibrinogen degradation products or Protein C for pre or post-menopausal women. There was no increase in the incidence of thromboembolic events on tamoxifen. This study demonstrates that tamoxifen has only marginal effects on factors involved in haemostasis reported to affect the incidence of arterial or venous thromboembolic disease. The follow-up time is relatively short (maximum 36 months) and careful long term follow-up is necessary to detect clinically significant morbidity. |
format | Text |
id | pubmed-1977438 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1992 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-19774382009-09-10 Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women. Jones, A. L. Powles, T. J. Treleaven, J. G. Burman, J. F. Nicolson, M. C. Chung, H. I. Ashley, S. E. Br J Cancer Research Article Tamoxifen has been implicated as a risk factor for venous thrombosis in advanced breast cancer although the evidence for increased arterial or venous thrombosis with tamoxifen in early breast cancer is less clear. The effect of tamoxifen on haemostasis, and thereby possible thromboembolic risk, was investigated in normal women enrolled in a placebo controlled trial of tamoxifen as a chemopreventative agent for breast cancer. There was an initial reduction in fibrinogen levels in all women on tamoxifen over the first year of follow-up and a marginal reduction in antithrombin III and Protein S in postmenopausal women at 6 months. There were no changes in cross linked fibrinogen degradation products or Protein C for pre or post-menopausal women. There was no increase in the incidence of thromboembolic events on tamoxifen. This study demonstrates that tamoxifen has only marginal effects on factors involved in haemostasis reported to affect the incidence of arterial or venous thromboembolic disease. The follow-up time is relatively short (maximum 36 months) and careful long term follow-up is necessary to detect clinically significant morbidity. Nature Publishing Group 1992-10 /pmc/articles/PMC1977438/ /pubmed/1419616 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Jones, A. L. Powles, T. J. Treleaven, J. G. Burman, J. F. Nicolson, M. C. Chung, H. I. Ashley, S. E. Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women. |
title | Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women. |
title_full | Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women. |
title_fullStr | Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women. |
title_full_unstemmed | Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women. |
title_short | Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women. |
title_sort | haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977438/ https://www.ncbi.nlm.nih.gov/pubmed/1419616 |
work_keys_str_mv | AT jonesal haemostaticchangesandthromboembolicriskduringtamoxifentherapyinnormalwomen AT powlestj haemostaticchangesandthromboembolicriskduringtamoxifentherapyinnormalwomen AT treleavenjg haemostaticchangesandthromboembolicriskduringtamoxifentherapyinnormalwomen AT burmanjf haemostaticchangesandthromboembolicriskduringtamoxifentherapyinnormalwomen AT nicolsonmc haemostaticchangesandthromboembolicriskduringtamoxifentherapyinnormalwomen AT chunghi haemostaticchangesandthromboembolicriskduringtamoxifentherapyinnormalwomen AT ashleyse haemostaticchangesandthromboembolicriskduringtamoxifentherapyinnormalwomen |